Pathology: non squamous - mNSCLC - L1 - all population; squamous - mNSCLC - L1 - all population;
| non squamous - mNSCLC - L1 - all population | squamous - mNSCLC - L1 - all population | ||
| IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018 | IMpower-131 (ACP) EXPLORATORY, 2020 | ||
| atezolizumab plus carboplatin plus paclitaxel | 2 | T1 | T1 |
| nab-paclitaxel | 0 | T0 | |
| bevacizumab plus carboplatin and paclitaxel | 0 | T0 |